Inhibikase Therapeutics, Inc. (IKT)
2025-06-30 | ||||
|---|---|---|---|---|
| Selling, general and administrative | 5,919,731 | |||
| Research and development | 5,270,967 | |||
| Change in fair value contingent consideration | 358,420 | |||
| Total costs and expenses | 10,832,278 | |||
| Loss from operations | -10,832,278 | |||
| Interest income | 916,755 | |||
| Net loss | -9,915,523 | |||
| Net loss per share - basic | -0.11 | |||
| Net loss per share - diluted | -0.11 | |||
| Weighted average number of shares outstanding, basic | 90,009,625 | |||
| Weighted average number of shares outstanding, diluted | 90,009,625 | |||